{"title":"机器人胃切除术是超重胃癌患者的可靠选择:倾向得分匹配研究","authors":"Ling-Hua Wei, Hua-Long Zheng, Zhen Xue, Bin-Bin Xu, Hong-Hong Zheng, Li-Li Shen, Zhi-Wei Zheng, Jian-Wei Xie, Chao-Hui Zheng, Chang-Ming Huang, Qi-Yue Chen, Ping Li","doi":"10.1007/s00464-024-10845-4","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>The role of minimally invasive surgery using robotics versus laparoscopy in resectable gastric cancer patients with a high body mass index (BMI) remains controversial.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A total of 482 gastric adenocarcinoma patients with BMI ≥ 25 kg/m<sup>2</sup> who underwent minimally invasive radical gastrectomy between August 2016 and December 2019 were retrospectively analyzed, including 109 cases in the robotic gastrectomy (RG) group and 321 cases in the laparoscopic gastrectomy (LG) group. Propensity score matching (PSM) with a 1:1 ratio was performed, and the perioperative outcomes, lymph node dissection, and 3-year overall survival (OS) and disease-free survival (DFS) rates were compared.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>After PSM, 109 patients were included in each of the RG and LG groups, with balanced baseline characteristics. Compared with the LG group, the RG group had similar intraoperative estimated blood loss [median (IQR) 30 (20–50) vs. 35 (30–59) mL, median difference (95%CI) − 5 (− 10 to 0)], postoperative complications [13.8% vs. 18.3%, OR (95%CI) 0.71 (0.342 to 1.473)], postoperative recovery, total harvested lymph nodes [(34.25 ± 13.43 vs. 35.44 ± 14.12, mean difference (95%CI) − 1.19 (− 4.871 to 2.485)] and textbook outcomes [(81.7% vs. 76.1%, OR (95%CI) 1.39 (0.724 to 2.684)]. Among pathological stage II–III patients receiving chemotherapy, the initiation of adjuvant chemotherapy in the RG group was similar to that in the LG group [median (IQR): 28 (25.5–32.5) vs. 32 (27–38.5) days, median difference (95%CI) − 3 (− 6 to 0)]. The 3-year OS (RG vs. LG: 80.7% vs. 81.7%, HR = 1.048, 95%CI 0.591 to 1.857) and DFS (78% vs. 76.1%, HR = 0.996, 95%CI 0.584 to 1.698) were comparable between the two groups.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>RG conferred comparable lymph node dissection, postoperative recovery, and oncologic outcomes in a selected cohort of patients with BMI ≥ 25 kg/m<sup>2</sup>.</p>","PeriodicalId":501625,"journal":{"name":"Surgical Endoscopy","volume":"188 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Robotic gastrectomy was reliable option for overweight patients with gastric cancer: a propensity score matching study\",\"authors\":\"Ling-Hua Wei, Hua-Long Zheng, Zhen Xue, Bin-Bin Xu, Hong-Hong Zheng, Li-Li Shen, Zhi-Wei Zheng, Jian-Wei Xie, Chao-Hui Zheng, Chang-Ming Huang, Qi-Yue Chen, Ping Li\",\"doi\":\"10.1007/s00464-024-10845-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3 data-test=\\\"abstract-sub-heading\\\">Background</h3><p>The role of minimally invasive surgery using robotics versus laparoscopy in resectable gastric cancer patients with a high body mass index (BMI) remains controversial.</p><h3 data-test=\\\"abstract-sub-heading\\\">Methods</h3><p>A total of 482 gastric adenocarcinoma patients with BMI ≥ 25 kg/m<sup>2</sup> who underwent minimally invasive radical gastrectomy between August 2016 and December 2019 were retrospectively analyzed, including 109 cases in the robotic gastrectomy (RG) group and 321 cases in the laparoscopic gastrectomy (LG) group. Propensity score matching (PSM) with a 1:1 ratio was performed, and the perioperative outcomes, lymph node dissection, and 3-year overall survival (OS) and disease-free survival (DFS) rates were compared.</p><h3 data-test=\\\"abstract-sub-heading\\\">Results</h3><p>After PSM, 109 patients were included in each of the RG and LG groups, with balanced baseline characteristics. Compared with the LG group, the RG group had similar intraoperative estimated blood loss [median (IQR) 30 (20–50) vs. 35 (30–59) mL, median difference (95%CI) − 5 (− 10 to 0)], postoperative complications [13.8% vs. 18.3%, OR (95%CI) 0.71 (0.342 to 1.473)], postoperative recovery, total harvested lymph nodes [(34.25 ± 13.43 vs. 35.44 ± 14.12, mean difference (95%CI) − 1.19 (− 4.871 to 2.485)] and textbook outcomes [(81.7% vs. 76.1%, OR (95%CI) 1.39 (0.724 to 2.684)]. Among pathological stage II–III patients receiving chemotherapy, the initiation of adjuvant chemotherapy in the RG group was similar to that in the LG group [median (IQR): 28 (25.5–32.5) vs. 32 (27–38.5) days, median difference (95%CI) − 3 (− 6 to 0)]. The 3-year OS (RG vs. LG: 80.7% vs. 81.7%, HR = 1.048, 95%CI 0.591 to 1.857) and DFS (78% vs. 76.1%, HR = 0.996, 95%CI 0.584 to 1.698) were comparable between the two groups.</p><h3 data-test=\\\"abstract-sub-heading\\\">Conclusion</h3><p>RG conferred comparable lymph node dissection, postoperative recovery, and oncologic outcomes in a selected cohort of patients with BMI ≥ 25 kg/m<sup>2</sup>.</p>\",\"PeriodicalId\":501625,\"journal\":{\"name\":\"Surgical Endoscopy\",\"volume\":\"188 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Surgical Endoscopy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s00464-024-10845-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgical Endoscopy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00464-024-10845-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
方法回顾性分析了2016年8月至2019年12月期间接受微创根治性胃切除术的482例体重指数≥25 kg/m2的胃腺癌患者,其中机器人胃切除术(RG)组109例,腹腔镜胃切除术(LG)组321例。结果经过倾向评分匹配(PSM),RG组和LG组各纳入109例患者,基线特征均衡。与 LG 组相比,RG 组的术中估计失血量[中位数(IQR)30 (20-50) mL vs. 35 (30-59) mL,中位数差异(95%CI)- 5 (- 10 to 0)]、术后并发症[13.8% vs. 18.3%,OR (95%CI) 0.71 (0.342 to 1.473)]、术后恢复、收获的淋巴结总数[(34.25 ± 13.43 vs. 35.44 ± 14.12,平均差(95%CI)- 1.19 (- 4.871 to 2.485)]和教科书结果[(81.7% vs. 76.1%,OR (95%CI) 1.39 (0.724 to 2.684)]。在接受化疗的病理分期为II-III期的患者中,RG组开始辅助化疗的时间与LG组相似[中位数(IQR):28(25.5-32.5)天 vs 32(27-38.5)天,中位数差异(95%CI)-3(-6至0)]。两组患者的 3 年 OS(RG vs. LG:80.7% vs. 81.7%,HR = 1.048,95%CI 0.591 至 1.857)和 DFS(78% vs. 76.1%,HR = 0.996,95%CI 0.584 至 1.698)相当。
Robotic gastrectomy was reliable option for overweight patients with gastric cancer: a propensity score matching study
Background
The role of minimally invasive surgery using robotics versus laparoscopy in resectable gastric cancer patients with a high body mass index (BMI) remains controversial.
Methods
A total of 482 gastric adenocarcinoma patients with BMI ≥ 25 kg/m2 who underwent minimally invasive radical gastrectomy between August 2016 and December 2019 were retrospectively analyzed, including 109 cases in the robotic gastrectomy (RG) group and 321 cases in the laparoscopic gastrectomy (LG) group. Propensity score matching (PSM) with a 1:1 ratio was performed, and the perioperative outcomes, lymph node dissection, and 3-year overall survival (OS) and disease-free survival (DFS) rates were compared.
Results
After PSM, 109 patients were included in each of the RG and LG groups, with balanced baseline characteristics. Compared with the LG group, the RG group had similar intraoperative estimated blood loss [median (IQR) 30 (20–50) vs. 35 (30–59) mL, median difference (95%CI) − 5 (− 10 to 0)], postoperative complications [13.8% vs. 18.3%, OR (95%CI) 0.71 (0.342 to 1.473)], postoperative recovery, total harvested lymph nodes [(34.25 ± 13.43 vs. 35.44 ± 14.12, mean difference (95%CI) − 1.19 (− 4.871 to 2.485)] and textbook outcomes [(81.7% vs. 76.1%, OR (95%CI) 1.39 (0.724 to 2.684)]. Among pathological stage II–III patients receiving chemotherapy, the initiation of adjuvant chemotherapy in the RG group was similar to that in the LG group [median (IQR): 28 (25.5–32.5) vs. 32 (27–38.5) days, median difference (95%CI) − 3 (− 6 to 0)]. The 3-year OS (RG vs. LG: 80.7% vs. 81.7%, HR = 1.048, 95%CI 0.591 to 1.857) and DFS (78% vs. 76.1%, HR = 0.996, 95%CI 0.584 to 1.698) were comparable between the two groups.
Conclusion
RG conferred comparable lymph node dissection, postoperative recovery, and oncologic outcomes in a selected cohort of patients with BMI ≥ 25 kg/m2.